NYSE:PFE
Pfizer Inc (PFE)
Financials 
Technical Analysis 
Sep 14, 2026, 12:00 amThis summary was created by AI, based on 27 opinions in the last 12 months.
Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.
Likes it. Slow and steady growth. Lots of cash and would benefit from an acquisition. Have proven themselves very good at execution. They lost Lipitor earlier in the year and managed to hold on to quite a good market share. It is inexpensive, as are all of those in the space. Big cash balance. 3.2% dividend.
Like other entities in the big Pharma space it is going to be really challenged from a growth perspective in the next little while. In general, no one should be over enthusiastic about the pipeline of new drugs at this stage. Because of their size, it is very difficult for them to grow. Governments are very constrained on what they are allowed to spend on healthcare.
Likes this stock. Pays a nice 3.7% dividend. You are not buying this necessarily for strong earnings per share growth long-term. You are buying it for cash flow and dividend yield. Growth rate of the dividend yield should be around 8.5% per year projected over the next 3 years.
Stan WongAll the drugs are moving. We are finally in a good space for them. Model of $28.28. 19% upside.
Brian Acker, CA
Don LatoBrian Acker, CAStan WongBrian Acker, CA
Norman Levine'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
A lot of pharmaceutical companies went through a period where they had incredibly wonderful drug product lines coming through. Were treated as though they were biotech companies and were given huge massive multiples because their products coming out where multibillion-dollar products. The reality is that pharmaceuticals come out with smaller products and these companies have been re-rated. Feels the stocks are cheap at 10X earnings with a very good dividend yield. Has the opportunity to grow at a reasonable rate.